Ranbaxy Presents Corrective Plans To U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories of India has presented U.S. FDA a "corrective action" plan to satisfy the agency's complaints about some of the drugs exported to the United States from certain Ranbaxy plants. An FDA spokesman agreed the agency and Ranbaxy are working to clear the problems raised by the FDA. Ranbaxy's new CEO, appointed by Japan's Daiichi Sankyo after buying Ranbaxy, said he expects the problems to be cleared and Ranbaxy given full FDA approval in a few months. (Click here for more